Page 1

INTERIM REPORT | JANUARY - SEPTEMBER 2021 | XINTELA AB ( PUBL ) xintela 2021 23 100 0 BALB 500 B Sta 039 FC XSTEM approaching clinical study in osteoarthritis patients In order to prepare and carry out the clinical study on patients with knee osteoarthritis , Xintela initiated collaboration with a CRO during the quarter and formed the subsidiary Xindu in Australia for administrating the study . Recruitment of patients for the study is expected to begin in early 2022 . XSTEM to clinic for treatment of difficult - to - heal leg ulcers After successful preclinical result , Xintela decided in the quarter to broaden the clinical development of XSTEM to include difficult- to - heal leg ulcers . A clinical study is planned to start in mid - 2022 . TARG10 selected as candidate drug for aggressive cancer After the end of the quarter , the subsidiary Targinta achieved a significant milestone by selecting drug candidate TARG10 for the treatment of triple - negative breast cancer .